These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 27864552)
1. Immune-Mediated Protection and Pathogenesis of Chikungunya Virus. Fox JM; Diamond MS J Immunol; 2016 Dec; 197(11):4210-4218. PubMed ID: 27864552 [TBL] [Abstract][Full Text] [Related]
2. Immunopathology of Chikungunya Virus Infection: Lessons Learned from Patients and Animal Models. Ng LFP Annu Rev Virol; 2017 Sep; 4(1):413-427. PubMed ID: 28637387 [TBL] [Abstract][Full Text] [Related]
3. Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation. Cook LE; Locke MC; Young AR; Monte K; Hedberg ML; Shimak RM; Sheehan KCF; Veis DJ; Diamond MS; Lenschow DJ J Virol; 2019 Dec; 94(1):. PubMed ID: 31619554 [TBL] [Abstract][Full Text] [Related]
4. Chikungunya Virus-Induced Arthritis: Role of Host and Viral Factors in the Pathogenesis. Amdekar S; Parashar D; Alagarasu K Viral Immunol; 2017 Dec; 30(10):691-702. PubMed ID: 28910194 [TBL] [Abstract][Full Text] [Related]
5. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. Her Z; Teng TS; Tan JJ; Teo TH; Kam YW; Lum FM; Lee WW; Gabriel C; Melchiotti R; Andiappan AK; Lulla V; Lulla A; Win MK; Chow A; Biswas SK; Leo YS; Lecuit M; Merits A; Rénia L; Ng LF EMBO Mol Med; 2015 Jan; 7(1):24-41. PubMed ID: 25452586 [TBL] [Abstract][Full Text] [Related]
6. Chikungunya virus pathogenesis and immunity. Gasque P; Couderc T; Lecuit M; Roques P; Ng LF Vector Borne Zoonotic Dis; 2015 Apr; 15(4):241-9. PubMed ID: 25897810 [TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880 [TBL] [Abstract][Full Text] [Related]
9. Cellular and molecular mechanisms of chikungunya pathogenesis. Lum FM; Ng LF Antiviral Res; 2015 Aug; 120():165-74. PubMed ID: 26092642 [TBL] [Abstract][Full Text] [Related]
10. A high-dose inoculum size results in persistent viral infection and arthritis in mice infected with chikungunya virus. Zhang Y; Yan H; Li X; Zhou D; Zhong M; Yang J; Zhao B; Fan X; Fan J; Shu J; Lu M; Jin X; Zhang E; Yan H PLoS Negl Trop Dis; 2022 Jan; 16(1):e0010149. PubMed ID: 35100271 [TBL] [Abstract][Full Text] [Related]
11. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis. Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993 [TBL] [Abstract][Full Text] [Related]
12. Cellular and Molecular Immune Response to Chikungunya Virus Infection. Tanabe ISB; Tanabe ELL; Santos EC; Martins WV; Araújo IMTC; Cavalcante MCA; Lima ARV; Câmara NOS; Anderson L; Yunusov D; Bassi ÊJ Front Cell Infect Microbiol; 2018; 8():345. PubMed ID: 30364124 [TBL] [Abstract][Full Text] [Related]
13. Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology. Jones JE; Long KM; Whitmore AC; Sanders W; Thurlow LR; Brown JA; Morrison CR; Vincent H; Peck KM; Browning C; Moorman N; Lim JK; Heise MT mBio; 2017 Nov; 8(6):. PubMed ID: 29138302 [TBL] [Abstract][Full Text] [Related]
14. Disease Resolution in Chikungunya-What Decides the Outcome? Srivastava P; Kumar A; Hasan A; Mehta D; Kumar R; Sharma C; Sunil S Front Immunol; 2020; 11():695. PubMed ID: 32411133 [TBL] [Abstract][Full Text] [Related]
15. Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis. Nayak K; Jain V; Kaur M; Khan N; Gottimukkala K; Aggarwal C; Sagar R; Gupta S; Rai RC; Dixit K; Islamuddin M; Khan WH; Verma A; Maheshwari D; Chawla YM; Reddy ES; Panda H; Sharma P; Bhatnagar P; Singh P; Raghavendhar B S; Patel AK; Ratageri VH; Chandele A; Ray P; Murali-Krishna K JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32155134 [TBL] [Abstract][Full Text] [Related]
16. Development of Vaccines for Chikungunya Fever. Erasmus JH; Rossi SL; Weaver SC J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179 [TBL] [Abstract][Full Text] [Related]
17. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455 [TBL] [Abstract][Full Text] [Related]
18. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. Poo YS; Rudd PA; Gardner J; Wilson JA; Larcher T; Colle MA; Le TT; Nakaya HI; Warrilow D; Allcock R; Bielefeldt-Ohmann H; Schroder WA; Khromykh AA; Lopez JA; Suhrbier A PLoS Negl Trop Dis; 2014 Dec; 8(12):e3354. PubMed ID: 25474568 [TBL] [Abstract][Full Text] [Related]
19. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody. Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287 [TBL] [Abstract][Full Text] [Related]
20. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]